trans-sodium-crocetinate and Cardiomegaly

Oxidative stress plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. Because crocetin represses oxidative stress in vitro and in vivo, we have suggested that crocetin would repress cardiac hypertrophy by targeting oxidative stress-dependent signalling. We tested this hypothesis using primary cultured cardiac myocytes and fibroblasts and one well-established animal model of cardiac hypertrophy. The results showed that crocetin (1-10 microM) dose-dependently blocked cardiac hypertrophy induced by angiogensin II (Ang II; 1 microM) in vitro. Our data further revealed that crocetin (50 mg/kg/day) both prevented and reversed cardiac hypertrophy induced by aortic banding (AB), as assessed by heart weight/body weight and lung weight/body weight ratios, echocardio-graphic parameters and gene expression of hypertrophic markers. The inhibitory effect of crocetin on cardiac hypertrophy is mediated by blocking the reactive oxygen species (ROS)-dependent mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase-1/2 (MEK/ERK1/2) pathway and GATA binding protein 4 (GATA-4) activation. Further investigation demonstrated that crocetin inhibited inflammation by blocking nuclear factor kappa B (NF-kappaB) signalling and attenuated fibrosis and collagen synthesis by abrogating MEK-ERK1/2 signalling. Overall, our results indicate that crocetin, which is a potentially safe and inexpensive therapy for clinical use, has protective potential in targeting cardiac hypertrophy and fibrosis by suppression of ROS-dependent signalling pathways.

Topics: Animals; Animals, Newborn; Antioxidants; Cardiomegaly; Carotenoids; Cell Size; Cells, Cultured; Collagen; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; GATA4 Transcription Factor; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Vitamin A

Crocetin, a carotenoid isolated from the Chinese herbal medicine Crocus sativus L. (Saffron), has been shown to have cardiovascular protective effects. The present study investigated the protective action of the antioxidant crocetin against cardiac hypertrophy induced by norepinephrine (NE). This was evaluated by assaying for pathological histological changes with an optical microscope and cell image analysis system. Lipid peroxidation was quantified using thiobarbituric acid-reactive substances (TBARS). Myocardial superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and myocardial catalase (CAT) activities were assayed to evaluate the antioxidant capacity. After long term treatment with NE, antioxidant enzymatic activities were significantly decreased, while products of lipid peroxidation increased. Crocetin markedly reduced the content of lipid peroxidation (LPO), increased the GSH-Px and SOD activity in cardiac hypertrophy, and significantly improved the myocardial pathological histological changes induced by NE. These results suggest that the cardioprotective effects of crocetin are related to modulation of endogenous antioxidant enzymatic activities. Comparing crocetin with captopril, our results indicated that antioxidant activity is an important factor in the therapy of cardiac hypertrophy, but as an antioxidant only, its effects may be limited.

Topics: Adrenergic alpha-Agonists; Animals; Antioxidants; Cardiomegaly; Carotenoids; Catalase; Female; Free Radical Scavengers; Glutathione Peroxidase; Lipid Peroxidation; Myocardium; Norepinephrine; Organ Size; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Vitamin A

To study the influence of crocetin on cardiac hypertrophy induced by overloading pressure in rats.. The model of cardiac hypertrophy was produced by overloading pressure in rats. The animals were divided into five groups: sham-operation group (0.5% CMC-Na, ig), model group (operation + 0.5% CMC-Na, ig), captopril group (operation + 50 mg x kg(-1), ig), crocetin I (100 mg x kg(-1), ig) and crocetin II (50 mg x kg(-1), ig). All animals were treated for 30 d by ig. Then, cardiac indexes were examined. The activity of ATPase and the hydroxyproline content in heart were assayed by colorimetric analysis. Matrix metalloproteinases (MMPs) activity was assayed by SDS-PAGE zymography.. Compared with the model group, crocetin was found to significantly reduce the cardiac indexes and the content of hydroxyproline in heart, increase the activity of Na+ , K+ -ATPase, Ca2+, Mg2+ -ATPase and inhibit MMPs activity.. The activity of MMPs may play a key role in the cardiac hypertrophy induced by overloading pressure, and proprably as a result of decreasing the activity of MMPs. Crocetin was shown to prevent remodeling of cardiac hypertrophy induced by overloading pressure.

Topics: Animals; Ca(2+) Mg(2+)-ATPase; Cardiomegaly; Carotenoids; Hydroxyproline; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Organ Size; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Vitamin A